Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Nivolumab & Non-small-cell lung cancer (NSCLC), In 2015, the FDA approved nivolumab as monotherapy for metastatic squamous and non‑squamous Non-small-cell lung cancer (NSCLC) after prior platinum‑based chemotherapy (1)
EMA has approved nivolumab for previously treated advanced Non-small-cell lung cancer (NSCLC) based on phase III trials versus docetaxel, covering both squamous and non‑squamous histologies (2, 3)
Nivolumab approval were independent of [PD-L1 status](brain://cKRGVQKxm0WaCEksEf6vDA/ProgrammedDeathligand1Pdl1Expressio…